Graham’s Foundation Co-Founder and President Nick Hall, representing the Parent Voice for the newly formed International Neonatal Consortium

Toledo-area resident playing a pivotal role in the launch  of the new consortium designed to speed the development of therapies for premature babies

nick hall preemie expertGraham’s Foundation (http://www.GrahamsFoundation.org), a Toledo-area non-profit that empowers parents of premature babies through support, advocacy and research to improve outcomes for their preemies and themselves, announced that Graham’s Foundation and Founder and President Nick Hall will be a key contributor to the newly formed International Neonatal Consortium (INC). Graham’s Foundation is proud to be a sponsor of the initiative and to have Mr. Hall representing the parent voice as moderator of the panel, Incorporating the Voice of Families, taking place May 18-19 in London at the European Medicines Agency workshop where the INC will officially launch.  

This newly-created coalition brings together industry, academia, patient representatives, the FDA, the European Medicines Agency, other governmental agencies, professional organizations, and the Critical Path Institute for the purpose of speeding up the development of therapies for premature babies.

“As Graham’s Foundation continues to delve deeper into the issues and challenges facing babies born prematurely, we are discovering that there is much work to be done,” said Mr. Hall, who founded Graham’s Foundation with his wife Jennifer after they experienced the birth of twins at just 25 weeks before facing the trials of the neonatal intensive care unit and the loss of their son, Graham. “We also understand that breakthrough solutions to improve outcomes for our preemies don’t happen overnight. We believe that including the voice of the parent throughout the process will lead to better targeted and more meaningful solutions for preemies and their families.”

The International Neonatal Consortium was created to accelerate the development of much-needed drugs for the earliest babies. The consortium will consider issues such as biomarkers, alternative trial design, extrapolation, and outcomes as it seeks to move science forward for the youngest, most fragile patients. Some of the first challenges facing the consortium will be defining “neonate” and better quantifying current standards of care.

About Graham’s Foundation

Graham’s Foundation empowers parents of premature babies through support, advocacy and research to improve outcomes for their preemies and themselves. We are committed to a world where no parent goes through the journey of prematurity alone. To fulfill our purpose, we rely on the generosity of volunteers, private donors and corporate sponsors. Find out how you can be a part of our mission at www.grahamsfoundation.org.

About the International Neonatal Consortium

INC is an international coalition of industry, academia, patient representatives, FDA, European Medicines Agency, other governmental agencies, professional organizations, and the Critical Path Institute (C-Path) that will focus on accelerating the development of therapeutics for the neonatal population.

 

Share This Post...

About The Author: Graham's Foundation

Graham's Foundation